Literature DB >> 27528549

Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.

Daniel Cejka1, Diego Parada-Rodriguez2, Stefanie Pichler2, Rodrig Marculescu3, Ina Kramer4, Michaela Kneissel4, Thomas Gross5, Andreas Reisinger5, Dieter Pahr5, Marie-Claude Monier-Faugere6, Martin Haas2, Hartmut H Malluche6.   

Abstract

Renal osteodystrophy affects the majority of patients with advanced chronic kidney disease (CKD) and is characterized by progressive bone loss. This study evaluated the effects of sclerostin knockout on bone in a murine model of severe, surgically induced CKD in both sclerostin knockout and wild-type mice. Mice of both genotypes with normal kidney function served as controls. Tibiae were analyzed using micro-computed tomography, and lumbar vertebrae were analyzed by histomorphometry. Results were tested for statistical significance by 2-way ANOVA to investigate whether bone of the knockout mice reacted differently to CKD compared with bone of wild-type mice. In the tibiae, there was no difference after creation of CKD between wild-type and knockout animals for cortical thickness or cross-sectional moment of inertia. Increases in cortical porosity induced by CKD differed significantly between genotypes in the tibial metaphysis but not in the diaphysis. In the trabecular compartment, no difference in reaction to CKD between genotypes was found for bone volume, trabecular number, trabecular thickness, and trabecular separation. In the lumbar vertebrae, significant differences in response to CKD between wild-type and knockout mice were seen for both bone volume and trabecular thickness. Osteoblast parameters did not differ significantly, whereas osteoclast numbers significantly increased in the wild-type but significantly decreased in knockout mice with CKD. No differences in response to CKD between genotypes were found for bone formation rate or mineral apposition rate. Thus, complete absence of sclerostin has only minor effects on CKD-induced bone loss in mice.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bone; kidney disease; mouse; renal osteodystrophy; sclerostin

Mesh:

Substances:

Year:  2016        PMID: 27528549      PMCID: PMC5530366          DOI: 10.1016/j.kint.2016.06.019

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  35 in total

1.  Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.

Authors:  Michael S Ominsky; Fay Vlasseros; Jacquelin Jolette; Susan Y Smith; Brian Stouch; George Doellgast; Jianhua Gong; Yongming Gao; Jin Cao; Kevin Graham; Barbara Tipton; Jill Cai; Rohini Deshpande; Lei Zhou; Michael D Hale; Daniel J Lightwood; Alistair J Henry; Andrew G Popplewell; Adrian R Moore; Martyn K Robinson; David L Lacey; W Scott Simonet; Chris Paszty
Journal:  J Bone Miner Res       Date:  2010-05       Impact factor: 6.741

2.  Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7.

Authors:  Esther A González; Richard J Lund; Kevin J Martin; John E McCartney; M Mehrdad Tondravi; T Kuber Sampath; Keith A Hruska
Journal:  Kidney Int       Date:  2002-04       Impact factor: 10.612

3.  Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.

Authors:  Sophie A Jamal; Douglas C Bauer; Kristine E Ensrud; Jane A Cauley; Marc Hochberg; Areef Ishani; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2007-04       Impact factor: 6.741

4.  Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat.

Authors:  H Zhou; V Shen; D W Dempster; R Lindsay
Journal:  J Bone Miner Res       Date:  2001-07       Impact factor: 6.741

5.  Relationship between moderate to severe kidney disease and hip fracture in the United States.

Authors:  Thomas L Nickolas; Donald J McMahon; Elizabeth Shane
Journal:  J Am Soc Nephrol       Date:  2006-09-27       Impact factor: 10.121

6.  Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.

Authors:  Yves Sabbagh; Fabiana Giorgeti Graciolli; Stephen O'Brien; Wen Tang; Luciene Machado dos Reis; Susan Ryan; Lucy Phillips; Joseph Boulanger; Wenping Song; Christina Bracken; Shiguang Liu; Steven Ledbetter; Paul Dechow; Maria Eugenia F Canziani; Aluizio B Carvalho; Vanda Jorgetti; Rosa M A Moyses; Susan C Schiavi
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

7.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

8.  Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure.

Authors:  Koba A Lomashvili; Marie-Claude Monier-Faugere; Xiaonan Wang; Hartmut H Malluche; W Charles O'Neill
Journal:  Kidney Int       Date:  2009-01-07       Impact factor: 10.612

9.  Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Authors:  Xiaodong Li; Michael S Ominsky; Qing-Tian Niu; Ning Sun; Betsy Daugherty; Diane D'Agostin; Carole Kurahara; Yongming Gao; Jin Cao; Jianhua Gong; Frank Asuncion; Mauricio Barrero; Kelly Warmington; Denise Dwyer; Marina Stolina; Sean Morony; Ildiko Sarosi; Paul J Kostenuik; David L Lacey; W Scott Simonet; Hua Zhu Ke; Chris Paszty
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

10.  Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice.

Authors:  Ina Kramer; Gabriela G Loots; Anne Studer; Hansjoerg Keller; Michaela Kneissel
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

View more
  6 in total

1.  Time course of rapid bone loss and cortical porosity formation observed by longitudinal μCT in a rat model of CKD.

Authors:  Erin M B McNerny; Dorothy T Buening; Mohammad W Aref; Neal X Chen; Sharon M Moe; Matthew R Allen
Journal:  Bone       Date:  2019-05-03       Impact factor: 4.398

Review 2.  Transcriptomics: a Solution for Renal Osteodystrophy?

Authors:  Aline Martin; Valentin David
Journal:  Curr Osteoporos Rep       Date:  2020-06       Impact factor: 5.096

3.  Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors.

Authors:  H H Malluche; M-C Monier-Faugere; G Blomquist; D L Davenport
Journal:  Osteoporos Int       Date:  2017-10-09       Impact factor: 4.507

Review 4.  Role of the Wnt/β-Catenin Pathway in Renal Osteodystrophy.

Authors:  Sarah-Kim Bisson; Roth-Visal Ung; Fabrice Mac-Way
Journal:  Int J Endocrinol       Date:  2018-04-02       Impact factor: 3.257

5.  Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.

Authors:  Florence Lima; Hanna Mawad; Amr A El-Husseini; Daniel L Davenport; Hartmut H Malluche
Journal:  Clin Nephrol       Date:  2019-04       Impact factor: 0.975

6.  A New Murine Model of Chronic Kidney Disease-Mineral and Bone Disorder.

Authors:  Bianca Frauscher; Katharina Artinger; Alexander H Kirsch; Ida Aringer; Foteini Moschovaki-Filippidou; Máté Kétszeri; Corinna Schabhüttl; Peter P Rainer; Albrecht Schmidt; Tatjana Stojakovic; Astrid Fahrleitner-Pammer; Alexander R Rosenkranz; Philipp Eller; Kathrin Eller
Journal:  Int J Endocrinol       Date:  2017-12-14       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.